Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
Retrieved on:
Thursday, May 11, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, Abstract, TET2, DNA, European Hematology Association, TI, Imetelstat, Chromosome, Infection, RNA, VAF, MDS, Corporation, ASXL1, Geron Corporation, Patient, Risk, CEST, Cytopenia, EHA, Public, RS, Transfusion-associated circulatory overload, DNA methylation, Gene, Thrombocytopenia, RNA splicing, Fatigue, Pharmaceutical industry, DNMT3A, SF3B1
The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.
Key Points:
- The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.
- As reported in January, 39.8% (47/118) of imetelstat-treated patients versus 15.0% (9/60) of placebo-treated patients achieved the study primary endpoint of 8-week TI (P
- As noted in the abstract, a main therapeutic goal in lower risk MDS is to alter disease biology by eradicating malignant clones.
- Of the 178 patients enrolled in IMerge Phase 3, 22.0% of imetelstat-treated patients and 21.7% of placebo-treated patients had baseline cytogenetic abnormalities.